European Biotechs Mull Going To Market Without Big Pharma Partners
European biotech companies that have lead products turned down by big pharma are now considering the benefits of taking drugs through late-stage development themselves; more funding options, such as concluding an IPO in the U.S. or Europe, is driving some of this change.
You may also be interested in...
The Vienna-based biotech looks to U.S. expertise to develop new mechanism-of-action antibacterial in go-it-alone strategy.
French drug delivery company, Adocia, raises $33 million to develop new formulations of therapeutic proteins for wound healing, diabetes
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.